Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
Opus Genetics (Nasdaq: IRD) secured a strategic financing facility with Oberland Capital that provides up to $155 million of primarily non-dilutive capital, including an $35 million initial tranche and a concurrent $5 million equity investment at $4.48 per share.
With ~$100 million pro forma cash, Opus says this extends runway into 2029 to complete pivotal OPGx-LCA5 and OPGx-BEST1 studies and to advance three earlier-stage programs toward clinical testing in 2026–2027.
Loading...
Loading translation...
Positive
Up to $155M non-dilutive financing facility
Initial $35M tranche plus $5M equity at $4.48/share
Cash runway extended into 2029 to cover pivotal studies
Three earlier-stage programs targeted to enter clinic 2026–2027
Negative
Up to 10% of each note principal convertible into shares at $6.72, creating potential dilution
Notes mature in 7 years with a lump-sum 50% repayment due on year six
Interest-only first six years with floating rate and PIK for 50% of interest increases effective cost
News Market Reaction – IRD
+1.32%
15 alerts
+1.32%News Effect
+3.0%Peak in 30 hr 27 min
+$5MValuation Impact
$350.41MMarket Cap
0.8xRel. Volume
On the day this news was published, IRD gained 1.32%, reflecting a mild positive market reaction.
Argus tracked a peak move of +3.0% during that session.
Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
This price movement added approximately $5M to the company's valuation, bringing the market cap to $350.41M at that time.
Non-dilutive funding capacity:$155 millionInitial note tranche:$35 millionEquity investment:$5 million+5 more
8 metrics
Non-dilutive funding capacity$155 millionTotal potential under Oberland note facility
Initial note tranche$35 millionTo be funded at initial closing of Oberland facility
Equity investment$5 millionCommon stock purchase by Oberland at $4.48 per share
Current cash balanceApproximately $100 millionIncluding initial $35M notes and $5M equity at closing
Additional non-dilutive capital$120 millionFurther access under Oberland facility beyond current cash
Initial cash interest rate4.1%Approximate initial cash interest rate on notes at closing
Note maturity7 yearsMaturity of notes after issuance of initial tranche
Convertible note portionUp to 10%Principal amount convertible at $6.72 per share at Oberland’s option
Market Reality Check
Price:$5.15Vol:Volume 346,854 is below 2...
low vol
$5.15Last Close
VolumeVolume 346,854 is below 20-day average 886,590 (relative volume 0.39x), suggesting a subdued pre-news setup.low
TechnicalShares at $4.55 are trading above the 200-day MA of $2.19, after a -2.99% move ahead of this financing news.
Peers on Argus
Ahead of this news, IRD was down 2.99% while momentum peers showed a mixed pictu...
2 Up2 Down
Ahead of this news, IRD was down 2.99% while momentum peers showed a mixed picture: ENTX up 7.94%, ATRA up 2.81%, and ABOS/QNCX down around 3%. This mix points to stock-specific factors rather than a clean sector-wide move.
FDA accepted sNDA for phentolamine ophthalmic solution 0.75% for presbyopia.
Pattern Detected
Recent history shows mixed reactions to positive news: strong gains on favorable clinical data but selloffs on some recognition and regulatory milestones, indicating inconsistent news-to-price alignment.
Recent Company History
Over the last few months, Opus reported several key events: positive Phase 1/2 OPGx‑BEST1 data with a 12-letter visual gain and 23% CST reduction, FDA acceptance of a supplemental NDA for phentolamine with an October 17, 2026 PDUFA date, and recognition on Fast Company’s Most Innovative Companies 2026 list. Despite broadly constructive clinical and regulatory updates, price reactions have alternated between gains and pullbacks, underscoring uneven investor response to otherwise supportive catalysts.
Regulatory & Risk Context
Active S-3 Shelf
Shelf Active
Active S-3 Shelf Registration
2026-03-13
An effective S-3 shelf has been filed to register up to 7,374,632 common shares for resale by selling stockholders. These shares are issuable upon conversion of an equal number of Series B Non‑Voting Convertible Preferred shares after stockholder approval to increase authorized common stock. The Company will not receive proceeds from these resales.
Market Pulse Summary
This announcement highlights a long-term funding package from Oberland Capital, providing up to $155...
Analysis
This announcement highlights a long-term funding package from Oberland Capital, providing up to $155M in non‑dilutive capital plus a $5M equity investment, bringing cash to roughly $100M and extending runway into 2029. The facility is earmarked to advance OPGx‑LCA5, OPGx‑BEST1 and earlier programs toward pivotal studies. Alongside a recent S‑3 registering 7,374,632 resale shares and earlier insider tax‑related sales, investors may watch execution on trial timelines and future capital structure changes closely.
Key Terms
non-dilutive funding, gene therapy, Phase 1/2 trial, volume-weighted average price (VWAP), +4 more
8 terms
non-dilutive fundingfinancial
"Agreement includes up to $155 million in non-dilutive funding with an upfront payment..."
Non-dilutive funding is money a company raises that does not require issuing new shares or reducing existing owners’ percentage ownership, such as grants, certain loans, contract revenue, or licensing deals. It matters to investors because it lets a company finance growth or research without shrinking shareholder stakes or changing control, much like topping up a car’s gas tank instead of selling part of the car to pay for the trip.
gene therapymedical
"a clinical-stage biopharmaceutical company developing gene therapies to restore vision..."
Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.
Phase 1/2 trialmedical
"Three-month topline results from full Cohort 1 of Phase 1/2 trial with OPGx-BEST1..."
A phase 1/2 trial combines the earliest human safety testing with an initial look at whether a treatment works, typically starting by checking tolerability and side effects and then expanding to measure early signs of benefit and the best dose. For investors, results from these trials are an early indicator of a drug’s clinical promise and regulatory path: positive data can materially increase a company’s value and reduce development risk, while negative data can sharply lower expectations.
volume-weighted average price (VWAP)financial
"based on the trailing 30-trading days volume-weighted average price (VWAP) of $4.48..."
Volume-weighted average price (VWAP) is the average price of a security over a trading period where each trade’s price is weighted by how many shares were traded, so larger trades pull the average more than tiny ones. Investors and traders use VWAP as a benchmark to judge whether a trade was executed at a favorable price—similar to checking whether you paid more or less than the typical price when most people were buying or selling.
paid-in-kindfinancial
"50% of the interest due on each tranche of notes shall be paid-in-kind for the first 8 quarters..."
Paid-in-kind describes an arrangement where a borrower pays interest or returns not with cash but by issuing more of the same security (extra bonds or shares) or by increasing the loan balance. For investors this matters because it conserves the issuer’s cash but can dilute ownership or increase debt over time, changing expected cash payments, risk and the real value of an investment much like being paid with an IOU instead of cash.
conversion pricefinancial
"convertible, at Oberland Capital’s option, into shares... at a conversion price of $6.72 per share."
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
retinitis pigmentosamedical
"RHO addresses patients with retinitis pigmentosa caused by autosomal dominant mutations..."
Retinitis pigmentosa is a group of inherited disorders that slowly damage the light-sensing cells in the retina, causing progressive loss of peripheral and night vision and often leading to legal blindness. It matters to investors because the condition defines a clear patient population and long-term need for treatments, making clinical trial design, potential market size, and regulatory approval pathways central considerations when valuing companies developing diagnostics or therapies.
autosomal dominantmedical
"retinitis pigmentosa caused by autosomal dominant mutations in the rhodopsin protein..."
A pattern of genetic inheritance where a single altered copy of a gene on a non-sex chromosome is enough to cause a trait or disorder, meaning an affected person usually has a 50% chance of passing it to each child. For investors, autosomal dominant conditions matter because they shape how common a disease is, who qualifies for trials, demand for diagnostics and therapies, and the potential size and predictability of a market—think of one flawed blueprint in a pair that still determines the final product.
AI-generated analysis. Not financial advice.
- Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment -
- Strategic financing to accelerate development of earlier-stage gene therapy programs with three additional programs entering clinical testing over the next year -
- Current cash of approximately $100 million now extends cash runway into 2029, through expected completion of OPGx-LCA5 and OPGx-BEST1 pivotal studies, potential approvals, and the prospect to receive priority review vouchers -
- Three-month topline results from full Cohort 1 of Phase 1/2 trial with OPGx-BEST1 remain on track for mid-2026 -
RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics”, “Opus”, or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today a strategic financing agreement with Oberland Capital Management LLC (“Oberland Capital”) to accelerate the clinical development, manufacturing, and potential commercialization of its broad gene therapy pipeline to maximize shareholder value.
The new note facility provides Opus with access to future non-dilutive funding of up to $155 million to support its future strategic initiatives and growth, with an initial tranche of $35 million to be funded at the initial closing, a second $35 million tranche available at the Company’s option within the next twelve months, along with additional tranches up to $35 million available to Opus upon the occurrence of certain milestones. The facility also provides for up to $50 million in additional tranches at the mutual agreement of the parties. In addition, Oberland Capital committed to make a $5 million equity investment in the Company’s common stock at $4.48 per share, concurrently with the closing of the initial tranche above.
“With the early success of the LCA5 and BEST1 programs, we are at a pivotal moment in which acceleration of our pipeline can drive significant future value,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “This credit facility enables us to fully fund clinical development and initiate pre-launch activities for our BEST1 and LCA5 programs, as well as move the earlier-stage RDH12, MERTK, and RHO programs into the clinic. This facility allows us to leverage our noncore commercial phentolamine asset and provides the financial flexibility to focus on our gene therapy platform with expected completion of OPGx-LCA5 and OPGx-BEST1 pivotal studies, potential approvals, and the prospect to receive priority review vouchers.”
“With our current cash resources of approximately $100 million and access to an additional $120 million of non-dilutive capital, we have a strengthened position to accelerate advancement of our entire portfolio and expand the opportunity to deliver meaningful therapies to patients as quickly as possible,” concluded Dr. Magrath.
“Opus Genetics’ validated gene therapy platform represents one of the most promising approaches for restoring vision and preventing blindness in patients suffering from severe inherited retinal diseases and fully aligns with our investment strategy of partnering with companies developing innovative technologies that address areas of high unmet medical need,” said William Clifford, Partner at Oberland Capital. “With access to significant capital in the form of both debt and equity through our flexible investment structure, as well as its commercial-stage partnership involving Phentolamine Ophthalmic Solution 0.75%, Opus Genetics is optimally positioned to accelerate the development of its robust pipeline of therapeutic candidates.”
Opus Genetics plans to provide an update later in 2026 on its earlier stage programs, including OPGx-RDH12, OPGx-MERTK, and OPGx-RHO.
RDH12-LCA: This program is expected to enter the clinic in the U.S. in Q4 2026. OPGx-RDH12 is the second asset licensed from Dr. Jean Bennett’s lab and is partially funded through a partnership with the RDH12 Alliance to bring this program to the clinic. RDH12 is an IRD that affects children at an early age with a prevalence estimated to be 2,500 patients in the U.S. and 30,900 globally1.
MERTK: As previously announced, Opus’ OPGx-MERTK program is expected to enter the clinic at the end of 2026 in collaboration with the Department of Health - Abu Dhabi. The MENA (Middle East/North Africa) region has a very large proportion of the global MERTK patients where the prevalence is estimated to be 14,300 patients, along with 2,600 in the U.S. and 21,960 globally1.
RHO: This program is expected to enter the clinic in 2027. OPGx-RHO addresses patients with retinitis pigmentosa caused by autosomal dominant mutations in the rhodopsin protein utilizing a knock-down of the mutant rhodopsin and replacement with wild type rhodopsin protein. RHO affects 8,800 patients in the U.S. and approximately 30,000 globally1.
Under the terms of the note purchase agreement with Oberland Capital, and subject to the satisfaction of customary funding conditions, Opus:
Will issue an initial $35 million in notes at the initial closing, which is expected to occur on April 20, 2026;
Can access up to an additional $35 million in notes at any time during the first 12 months;
Can access an additional $35 million in notes on or prior to March 31, 2028, upon achievement of certain pre-determined milestones related to the potential regulatory approval of LCA5;
Can access up to $50 million through December 31, 2027, upon mutual agreement by both parties.
The notes will mature seven years after the issuance of the initial notes. The notes may be repaid in full at any time and carry an interest-only period of six years, with a repayment of 50% of the outstanding notes on the sixth anniversary. The notes will bear interest at a floating rate, which is subject to both a floor and a cap and 50% of the interest due on each tranche of notes shall be paid-in-kind for the first 8 quarters of such tranche and added to the outstanding principal. Based on these terms, the initial cash interest rate at closing is approximately 4.1%. Additionally, up to 10% of the principal amount of each note will be convertible, at Oberland Capital’s option, into shares of the Company’s common stock at a conversion price of $6.72 per share.
In addition, the Company has entered into a stock purchase and conversion agreement with affiliates of Oberland Capital for the private placement of 1.1 million shares of the Company’s common stock issued at closing, representing $5 million of gross proceeds based on the trailing 30-trading days volume-weighted average price (VWAP) of $4.48 per share. Closing of the purchase of shares under the stock purchase agreement is expected to occur concurrently with the closing of the initial issuance of notes under the note purchase agreement on April 20, 2026.
The Company has approximately $100 million in cash, taking into account the initial $35 million of notes and $5 million of equity to be purchased by Oberland Capital at closing. Additional details regarding this financing will be available in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
1Source: Triangle Insights Group Analysis, February 2026
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing a small-molecule therapy, Phentolamine Ophthalmic Solution 0.75%, beyond its approved use for pharmacologically induced mydriasis, with a supplemental new drug application under review for presbyopia and an ongoing Phase 3 pivotal trial for mesopic, low contrast conditions after keratorefractive surgery (dim light disturbances). The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
About Oberland Capital
Oberland Capital is a private investment firm formed in 2013 with assets under management in excess of $3.2 billion, focused exclusively on investing in the global healthcare industry and specializing in flexible investment structures customized to meet the specific needs of its transaction partners. Oberland Capital's broad suite of financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investments in traditional debt and equity. With a combination of deep industry knowledge and extensive structured finance experience, the Oberland Capital team has a history of creating value for its transaction partners. For more information, please visit www.oberlandcapital.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to the clinical development, clinical results, preclinical data, and future plans for Phentolamine Ophthalmic Solution 0.75%, OPGx-LCA5, OPGx-BEST1, RDH12, and earlier stage programs, and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, our subsequent Quarterly Reports on Form 10-Q, and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
Contacts:
Investors Jenny Kobin Remy Bernarda IR Advisory Solutions ir@opusgtx.com
What financing did Opus Genetics (IRD) announce on April 6, 2026?
Opus announced a note facility providing up to $155 million, including a $35 million initial tranche and a $5 million concurrent equity purchase. According to the company, the financing combines debt tranches and an equity investment by Oberland Capital to support clinical programs.
How does the Oberland Capital deal affect Opus Genetics' cash runway and timeline for pivotal studies?
The company says pro forma cash of approximately $100 million plus access to additional tranches extends runway into 2029. According to the company, this funding is intended to complete OPGx-LCA5 and OPGx-BEST1 pivotal studies and pre-launch activities.
What are the key repayment and conversion terms for the new Opus Genetics notes (IRD)?
Notes mature in 7 years, with an interest-only period of six years and 50% repayment on year six; up to 10% of principal is convertible at $6.72 per share. According to the company, interest begins at ~4.1% and includes PIK and caps/floors.
Which Opus Genetics programs are expected to enter the clinic following the April 2026 financing?
Opus expects OPGx-RDH12 to enter the U.S. clinic in Q4 2026, OPGx-MERTK by end of 2026, and OPGx-RHO in 2027. According to the company, these earlier-stage programs will be advanced with the new financing.
What immediate cash will Opus Genetics (IRD) have after the initial closing on April 20, 2026?
After the initial $35 million note tranche and the $5 million equity purchase, the company reports approximately $100 million in pro forma cash. According to the company, that figure reflects existing balances plus the initial financing proceeds.
How might the Oberland financing impact Opus Genetics shareholders and stock dilution (IRD)?
The facility includes convertible components and an equity purchase that may dilute shareholders: up to 10% of each note principal is convertible at $6.72 and 1.1 million shares are issued at $4.48. According to the company, conversion is at Oberland's option.
